The Claim
Fecal metagenomic analysis shows that 59% of patients with unexplained polyposis and colibactin-associated mutational signatures (SBS88/ID18) harbor pks genes in their stool, compared to 25% of patients without these signatures, indicating a significant enrichment of colibactin-producing bacteria in those with this molecular phenotype.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with unexplained polyps in the colon, those who have a specific DNA damage pattern linked to colibactin are more likely to carry bacteria in their gut that produce colibactin, compared to those without this DNA pattern.
See the scientific wording
Fecal metagenomic analysis reveals that 59% of unexplained polyposis patients with colibactin-associated mutational signatures (SBS88/ID18) carry pks genes in their stool, compared to 25% of those without these signatures, indicating a significant enrichment of colibactin-producing bacteria in patients with this molecular phenotype.
What the research says
1 studyScientists found that people with a specific type of DNA damage in their colon are much more likely to have harmful bacteria in their stool that produce a cancer-causing toxin — this matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.